Abstract
Introduction
To evaluate the value of image-based texture analysis for predicting progression-free survival (PFS) and overall survival (OS) in patients with metastatic clear cell renal carcinoma (cCCR) treated with nivolumab.
Methods
This retrospective study included 48 patients with metastatic cCCR treated with nivolumab. Nivolumab was used as a second- or third-line monotherapy. Texture analysis of metastatic lesions was performed on CT scanners obtained within 1 month before treatment. Texture features related to the gray-level histogram, gray-level co-occurrence, run-length matrix features, autoregressive model features, and Haar wavelet feature were extracted. Lasso penalized Cox regression analyses were performed to identify independent predictors of PFS and OS.
Results
Median PFS and OS were 5.7 and 13.8 months. 39 patients experienced progression and 27 died. The Lasso penalized Cox regression analysis identified three texture parameters as potential predictors of PFS: skewness, S.2.2. Correlat and S.1.1. SumVarnc. Multivariate Cox regression analysis confirmed skewness (HR (95% CI) 1.49 [1.21–1.85], p < 0.001) as an independent predictor of PFS. Regarding OS, the Lasso penalized Cox regression analysis identified three texture parameters as potential predictors of OS: S20SumVarnc, S22Contrast and S22Entropy. Multivariate Cox regression analysis confirmed S22Entropy (HR (95% CI) 1.68 (1.31–2.14), p < 0.001) as an independent predictor of OS.
Conclusions
Results from this preliminary study suggest that CT texture analysis might be a promising quantitative imaging tool that predicts oncological outcomes after starting nivolumab treatment.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10147-021-02003-w/MediaObjects/10147_2021_2003_Fig1_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10147-021-02003-w/MediaObjects/10147_2021_2003_Fig2_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10147-021-02003-w/MediaObjects/10147_2021_2003_Fig3_HTML.png)
Similar content being viewed by others
References
Escudier B, Porta C, Schmidinger M et al (2019) Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 30:706–720
Thana M, Wood LA (2019) What do international guidelines say about first-line therapy for clear-cell metastatic renal cell carcinoma? Eur Urol Focus. https://doi.org/10.1016/j.euf.2019.09.014
Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803–1813
Motzer RJ, Tannir NM, McDermott DF et al (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378:1277–1290
Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus everolimus in advanced renal cell carcinoma. N Engl J Med 373:1803–1813
Wan X, Zhang Y, Tan C et al (2019) First-line nivolumab plus ipilimumab vs sunitinib for metastatic renal cell carcinoma: a cost-effectiveness analysis. JAMA Oncol 5:491
Sarfaty M, Leshno M, Gordon N et al (2018) Cost effectiveness of nivolumab in advanced renal cell carcinoma. Eur Urol 73:628–634
Dudani S, Savard M-F, Heng DYC (2020) An update on predictive biomarkers in metastatic renal cell carcinoma. Eur Urol Focus 6:34–36
Lambin P, Leijenaar RTH, Deist TM et al (2017) Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 14:749–762
Trebeschi S, Drago SG, Birkbak NJ et al (2019) Predicting response to cancer immunotherapy using non-invasive radiomic biomarkers. Ann Oncol. https://doi.org/10.1093/annonc/mdz108
Yun G, Kim YH, Lee YJ et al (2018) Tumor heterogeneity of pancreas head cancer assessed by CT texture analysis: association with survival outcomes after curative resection. Sci Rep. https://doi.org/10.1038/s41598-018-25627-x
Kim J-H, Ko ES, Lim Y et al (2017) Breast cancer heterogeneity: mr imaging texture analysis and survival outcomes. Radiology 282:665–675
Lubner MG, Stabo N, Lubner SJ et al (2015) CT textural analysis of hepatic metastatic colorectal cancer: pre-treatment tumor heterogeneity correlates with pathology and clinical outcomes. Abdom Imaging 40:2331–2337
Chee CG, Kim YH, Lee KH et al (2017) CT texture analysis in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy: a potential imaging biomarker for treatment response and prognosis. PloS One 12:e0182883
Nishino M, Jagannathan JP, Ramaiya NH et al (2010) Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know. Am J Roentgenol 195:281–289
Shafiq-Ul-Hassan M, Zhang GG, Latifi K et al (2017) Intrinsic dependencies of CT radiomic features on voxel size and number of gray levels. Med Phys 44:1050–1062
Szczypiński PM, Strzelecki M, Materka A et al (2009) MaZda–a software package for image texture analysis. Comput Methods Programs Biomed 94:66–76
Simon N, Friedman J, Hastie T et al (2011) Regularization paths for cox’s proportional hazards model via coordinate descent. J Stat Softw 39:1–13
Hothorn T, Lausen B (2002) On maximally selected rank statistics. R News 2:3–5
Durot C, Mulé S, Soyer P et al (2019) Metastatic melanoma: pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with pembrolizumab. Eur Radiol 29:3183–3191
Goh V, Ganeshan B, Nathan P et al (2011) Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. Radiology 261:165–171
Haider MA, Vosough A, Khalvati F et al (2017) CT texture analysis: a potential tool for prediction of survival in patients with metastatic clear cell carcinoma treated with sunitinib. Cancer Imaging. https://doi.org/10.1186/s40644-017-0106-8
McDermott DF, Choueiri TK, Motzer RJ et al (2019) CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features. J Clin Oncol 37:4513–4513
Roviello G, Corona SP, Nesi G et al (2019) Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter? Ther Adv Med Oncol 11:175883591986190
Semeniuk-Wojtaś A, Stec R, Szczylik C (2016) Are primary renal cell carcinoma and metastases of renal cell carcinoma the same cancer? Urol Oncol 34:215–220
Acknowledgement
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
About this article
Cite this article
Khene, Z., Kokorian, R., Mathieu, R. et al. Metastatic clear cell renal cell carcinoma: computed tomography texture analysis as predictive biomarkers of survival in patients treated with nivolumab. Int J Clin Oncol 26, 2087–2093 (2021). https://doi.org/10.1007/s10147-021-02003-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-021-02003-w